I’m also watching $Moderna, Inc.(MRNA)$ closely. Its Phase 3 cancer-vaccine success could be a major milestone for personalized medicine, although regulatory, manufacturing and commercialization risks remain.
Overall, I’m focusing less on short-term price movements and more on whether these breakthroughs can translate into durable earnings and cash flow. Different sectors, but the same investment question: how much future value can technology create?
@TigerEvents @Tiger_comments @TigerClub @TigerStars @WallStreet_Tiger
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.
- NicoleBryce·09-03 00:32TOPAI expanding the attack surface is the part I care about most. AI supply chain attacks were up around 40% last year, which is why platform security names like Palo Alto keep getting strongerLikeReport